温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.msd.com/media
点击访问原文链接

Media - MSD

进入原网站 导航首页
Media - MSD Skip to content

Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy MSD Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics and compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardiovascular disease Immunology Neuroscience Ophthalmology Areas of innovation Data science and artificial intelligence Green and sustainable science Our therapeutic modalities Translational medicine Pipeline Business development and licensing Clinical Trials Clinical trials overview Diversity in clinical trials R&D locations How we invent Meet our scientists Publications Safety data sheets (SDS) Product patents Patients Patients overview Play an active role in your health care Fighting counterfeit medicine Media Media overview News releases Company statements Company fact sheet Investors Investors overview Events and presentations Stock information Careers Who we are Learn more Contact us What can we help you find? Search for: Media Our media contacts and multimedia resources

News releasesCompany statements February 3, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

October 30, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

July 29, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

View all

February 3, 2026

MSD remembers Dr. William Foege, Architect of Early Mectizan® Delivery Efforts

January 8, 2026

MSD Statement on the U.S. Child and Adolescent Immunization Schedule

January 7, 2026

MSD to Complete Acquisition of Cidara Therapeutics

December 19, 2025

MSD Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

December 1, 2025

MSD Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025

November 17, 2025

MSD Commemorates 5 Billion Mectizan® Treatments Donated Over 38 Years

View all

Media contact details Global media relations

Phone icon +1 908-740-5633

Email icon mediarelations@msd.com

Media library Assets intended for use by media professionals.

These images are downloadable for non-commercial use and for purposes such as news reporting or research. The images may not be modified and must display the following copyright language: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Learn more about MSD’s copyright and trademark policies.

MSD corporate and product multimedia LogosPhotographyVideos Corporate brand MSD logo   Download

Leadership Robert M. Davis   Download Manufacturing Automated visual inspection of filled vials   Download Automated visual inspection of filled vials   Download Investigational COVID-19 antiviral Molnupiravir 1

  Download Headquarters, research and manufacturing B-roll package   Download Vaccine production B-roll package   Download Get to know us through our stories Everything we do, in and out of the laboratory, is based on our deep appreciation for life. Get a glimpse of what it’s like on the inside through our stories.

Read on We are driven by a single purpose We use the power of leading-edge science to save and improve lives around the world.

Learn more about our company × Pipeline

Our pipeline shows our relentless pursuit of the next breakthrough.

View our pipeline × Company fact sheet Access company information including stock ticker, official company names, description and more

See company fact sheet × Connect with us on social For patients and health care professionals MSD Manuals
Medical information source covering thousands of topics in all fields of medicine Clinical trials
Learn about our clinical trials and find available studies Sustainability Impact Report
Reporting on our commitment to operating responsibly to benefit society MSD for Mothers
An initiative to create a world where no woman has to die giving life About MSD MSD Animal Health
The global animal health business unit of MSD Contact Us
If you have a question or need more information about us, find out who you should contact. Forward-looking statementCookie policyCookie PreferencesPrivacyTerms of useAccessibilitySitemap Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

智能索引记录